Meet the Proteona team at the 11th AFOB Regional Symposium (ARS) conference in Singapore
Innovative genomic and proteomic analysis platform for Immuno-Oncology and Single Cell BioMedical Applications
Proteona announced that Dr Jonathan Scolnick will present at Asian Federation of Biotechnology (AFOB) Regional Symposium (ARS) conference in Singapore on the 24th January, 2019.
Dr Scolnick will share on Proteona's recent development on combining protein and gene expression to investigate the manufacturing of cell therapies.
For media queries, please contact:
Dr Andreas Schmidt
Proteona Pte. Ltd. is a biomedical company in Singapore, Germany, and the US that is pioneering the use of single cell proteogenomics to improve clinical outcomes in cancer. Using a combination of innovative single cell assays and AI-assisted bioinformatics, Proteona provides a comprehensive sample to answer service that enables users to phenotype cells using standard protein markers and gain a deeper understanding of cell activity based upon their gene expression profiles. Proteona is a spin-off from the National University of Singapore (NUS) and the Agency for Science, Technology and Research (A*STAR). Proteona is leading an international alliance to develop neutralizing antibodies against coronaviruses including SARS-CoV-2. In addition, Proteona supports partners developing COVID-19 therapies and vaccines by providing single cell immune profiling services.